BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
JP Morgan initiates Aurobindo Pharma with overweight
JP Morgan has initiated coverage on Aurobindo Pharma with a "overweight" rating. Expect 18 per cent CAGR in earnings over FY17-19. US is a key growth driver with improved execution. Debt reduction to be key trigger over next 2 years. Estimate margin expansion of 150 basis points by FY18.